GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » EV-to-Revenue

Essex Bio-Technology (HKSE:01061) EV-to-Revenue : 0.73 (As of Jun. 03, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Essex Bio-Technology's enterprise value is HK$1,243 Mil. Essex Bio-Technology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,707 Mil. Therefore, Essex Bio-Technology's EV-to-Revenue for today is 0.73.

The historical rank and industry rank for Essex Bio-Technology's EV-to-Revenue or its related term are showing as below:

HKSE:01061' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.57   Med: 3.14   Max: 6.04
Current: 0.73

During the past 13 years, the highest EV-to-Revenue of Essex Bio-Technology was 6.04. The lowest was 0.57. And the median was 3.14.

HKSE:01061's EV-to-Revenue is ranked better than
86.19% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs HKSE:01061: 0.73

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-03), Essex Bio-Technology's stock price is HK$2.59. Essex Bio-Technology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.87. Therefore, Essex Bio-Technology's PS Ratio for today is 0.90.


Essex Bio-Technology EV-to-Revenue Historical Data

The historical data trend for Essex Bio-Technology's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology EV-to-Revenue Chart

Essex Bio-Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.76 2.38 1.67 1.78 0.70

Essex Bio-Technology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 - 1.78 - 0.70

Competitive Comparison of Essex Bio-Technology's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Essex Bio-Technology's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Essex Bio-Technology's EV-to-Revenue falls into.



Essex Bio-Technology EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Essex Bio-Technology's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1243.250/1706.556
=0.73

Essex Bio-Technology's current Enterprise Value is HK$1,243 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Essex Bio-Technology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,707 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Essex Bio-Technology  (HKSE:01061) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Essex Bio-Technology's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.59/2.865
=0.90

Essex Bio-Technology's share price for today is HK$2.59.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.87.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Essex Bio-Technology EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Essex Bio-Technology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Essex Bio-Technology (HKSE:01061) Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.
Executives
Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin 2101 Beneficial owner

Essex Bio-Technology (HKSE:01061) Headlines

No Headlines